Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 30, 2015 3:31 PM ET

Healthcare Providers and Services

Company Overview of Quest Diagnostics Inc.

Company Overview

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV...

3 Giralda Farms

Madison, NJ 07940

United States

Founded in 1967

45,000 Employees

Phone:

973-520-2700

Key Executives for Quest Diagnostics Inc.

Chief Executive Officer, President, Director and Member of Executive Committee
Age: 57
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice President
Age: 52
Total Annual Compensation: $550.0K
Senior Vice President of Operations
Age: 51
Total Annual Compensation: $536.5K
Chief Medical Officer, Senior Vice President and Group Executive of Diagnostic Solutions Businesses
Age: 59
Total Annual Compensation: $573.9K
Senior Vice President and Group Executive of Clinical Franchise Solutions
Age: 51
Total Annual Compensation: $534.6K
Compensation as of Fiscal Year 2014.

Quest Diagnostics Inc. Key Developments

Quest Diagnostics Declares Quarterly Dividend Payable on July 22, 2015

Quest Diagnostics announced it will pay a quarterly dividend on its common stock of $0.38 per share on July 22, 2015 to shareholders of record on July 8, 2015.

Quest Diagnostics Launches QNatal Advanced

Quest Diagnostics launched QNatal Advanced, a noninvasive prenatal screening service for detecting chromosomal abnormalities in high-risk pregnancies. QNatal Advanced analyzes cell-free fetal DNA in circulating maternal blood to screen for common and rare chromosomal abnormalities, including those associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome), as well as fetal sex aneuploidies and select copy number variants. The screening test analyzes more chromosomal regions than most other noninvasive prenatal tests, and can be used as early as 10 weeks into gestation. With results of a QNatal Advanced screen, a woman and her physician may be better positioned to assess the appropriateness of invasive diagnostic testing, such as amniocentesis, which carries a slight risk of miscarriage, to confirm a finding.

Quest Diagnostics Announces LeukoVantage, Advancing Precision Medicine for Hematologic Malignancies

Quest Diagnostics announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs). For MDS, LeukoVantage may detect certain molecular markers to help identify early stages of the disease, complementing conventional diagnostic techniques. MDS is typically diagnosed through a series of tests that include complete blood count (CBC), morphology, and cytogenetic (chromosomal) analysis. For MPN, LeukoVantage may identify molecular markers that can aid the selection of certain targeted therapies, such as JAK2 inhibitors, and establishing a prognosis.

Similar Private Companies By Industry

Company Name Region
Hospital Administrative District 4 United States
James Lawrence Kernan Hospital, Inc. United States
Deseret Healthcare Inc. United States
Mercy Capitol United States
OhioHealth Heart & Vascular Physicians United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Quest Diagnostics Inc., please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.